Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Case-Based Acne and Rosacea Treatment Pearls for Clinical Practice
Description
This case-based discussion on acne and rosacea emphasized practical treatment choices and faster, more effective escalation strategies. For adult acne, the panel favored starting with a fixed triple topical combination (adapalene, clindamycin, benzoyl peroxide), noting its rapid onset and strong efficacy, and adding clascoterone early if needed rather than as a rescue. They argued that oral antibiotics should be used more sparingly, preferring doxycycline over minocycline for safety, avoiding prolonged courses, and stopping once patients are substantially improved rather than tapering; if response is inadequate after a few months, isotretinoin should be considered instead of repeating antibiotics. For spironolactone, they recommended waiting until menarche has occurred and then 1–2 years before use, typically starting at 50 mg and titrating to 100 mg, recognizing that hormonal therapies work slowly and often need a faster-acting topical alongside them. In pregnancy, treatment should not be withheld entirely; safer options include azelaic acid, benzoyl peroxide, clindamycin, and selected oral antibiotics such as amoxicillin, cephalexin, azithromycin, or erythromycin. They also reviewed isotretinoin flare management, advising against increasing the dose during an explosive flare, instead using systemic steroids, pausing isotretinoin if necessary, then reintroducing it slowly at low dose. For rosacea, they stressed identifying all phenotype features rather than relying on subtypes, since redness, papules, telangiectasia, flushing, and ocular disease often require different treatments. They highlighted that neurogenic rosacea is a pain-dominant condition that may respond to neuropathic pain medications, botulinum toxin, compounded pain creams, and possibly vagus nerve stimulation, while standard vascular treatments can sometimes worsen symptoms.
View moreConclusions
- For moderate acne, the panel favors starting with a fixed-dose topical triple combination because it works quickly and can outperform oral antibiotics in many cases.
- Oral isotretinoin remains the most effective acne treatment and should be reached sooner in patients with longstanding, severe, or treatment-refractory acne.
- Clascoterone is viewed as a useful add-on rather than a rescue monotherapy because hormonal-pathway treatments tend to act more slowly.
- Antibiotic stewardship should be stricter, with doxycycline preferred over minocycline for safety, and oral antibiotics reserved for limited durations or as adjuncts.
- The traditional three-month limit for acne antibiotics was described as arbitrary, and therapy should instead be stopped once the patient is substantially better or switched if response is inadequate.
- If acne does not improve after a few months of antibiotics, repeated antibiotic courses should be avoided and isotretinoin should be considered instead.
- Spironolactone is generally used after menarche and often started around 50 mg daily, with 50 to 100 mg daily seen as the practical range for acne.
- Pregnant patients should still be treated rather than left untreated, using safer options such as azelaic acid, benzoyl peroxide, clindamycin, and selected oral antibiotics when needed.
- Severe isotretinoin-induced flares or acne fulminans should be managed by stopping or lowering isotretinoin and using systemic corticosteroids before very slowly reintroducing isotretinoin at low dose.
- Rosacea should be managed by matching therapy to the specific features present, because redness, papules, telangiectasia, and ocular disease often require different treatments.
- Neurogenic rosacea is characterized by disproportionate burning and pain, often needs neuropathic pain approaches rather than standard rosacea therapy, and may respond poorly to typical topical agents.
- Transcutaneous auricular vagus nerve stimulation is an emerging nonpharmacologic option that may help refractory vascular or neurogenic rosacea by shifting autonomic balance toward a calming response.
- Huang CY, Chang IJ, Bolick N, et al. Ann Fam Med. 2023 Jul-Aug;21(4):358-369.
- Selvaraj, Katina J. et al. JAAD Reviews, Volume 5, 63 - 70.
- Ly S, Kamal K, Manjaly P, Barbieri JS, Mostaghimi A. Dermatol Ther (Heidelb). 2023 Jan;13(1):115-130.
- Greywal, Journal of the American Academy of Dermatology, 2017-07-01, Volume 77, Issue 1, Pages 109-117.
- ROSCO project 2019: Updated treatment algorithm. British Journal of Dermatology.